计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| T129642-5mg |
5mg |
现货 ![]() |
| |
| T129642-10mg |
10mg |
现货 ![]() |
| |
| T129642-25mg |
25mg |
现货 ![]() |
| |
| T129642-50mg |
50mg |
现货 ![]() |
| |
| T129642-100mg |
100mg |
期货 ![]() |
|
| 英文别名 | BCP02504 | J-504118 | HMS3265P03 | Torin 1 is known as a selective mTOR inhibitor. | AS-55924 | s2827 | AC-31516 | CCG-270213 | RHODAQUAT M-214C/99 | A850038 | InChI=1/C7H12O4/c1-10-6(8)4-3-5-7(9)11-2/h3-5H2,1-2H | MFCD18782653 | NCGC00263215-06 | EX-A397 |
|---|---|
| 规格或纯度 | Moligand™, ≥97% |
| 英文名称 | Torin 1 |
| 生化机理 | Torin 1 是一种强效的选择性 mTOR 抑制剂(对 mTORC1 和 mTORC2 的 IC50 = 2 - 10 nM)。Torin1 对 mTOR 的选择性是 DNA-PK、ATM 和 hVps34 的 200 倍。这种强效、选择性、ATP 竞争性 mTOR 抑制剂可直接抑制 mTORC1 和 mTORC2 复合物,在体外激酶试验中的 IC50 值介于 2 和 10 nM 之间。对 mTOR 的选择性是 PI3K 的 1000 倍,对 mTOR 的选择性是 PI3K 的 200 倍。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 雷帕霉素激酶机制靶点抑制剂 |
| 产品介绍 |
Product Description: Torin 1 is an effective inhibitor of mTORC1/2 with (IC50: 2 nM/10 nM); has 1000-fold selectivity for mTOR than PI3K. |
| 纯度 | ≥97% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504770944 |
|---|---|
| 分子类型 | 小分子 |
| IIUPAC Name | 1-[4-(4-propanoylpiperazin-1-yl)-3-(trifluoromethyl)phenyl]-9-quinolin-3-ylbenzo[h][1,6]naphthyridin-2-one |
| INCHI | 1S/C35H28F3N5O2/c1-2-32(44)42-15-13-41(14-16-42)31-11-9-26(19-28(31)35(36,37)38)43-33(45)12-8-24-20-40-30-10-7-22(18-27(30)34(24)43)25-17-23-5-3-4-6-29(23)39-21-25/h3-12,17-21H,2,13-16H2,1H3 |
| InChi Key | AKCRNFFTGXBONI-UHFFFAOYSA-N |
| Smiles | CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F |
| Isomeric SMILES | CCC(=O)N1CCN(CC1)C2=C(C=C(C=C2)N3C(=O)C=CC4=CN=C5C=CC(=CC5=C43)C6=CC7=CC=CC=C7N=C6)C(F)(F)F |
| PubChem CID | 49836027 |
| 分子量 | 607.62 |
| 溶解性 | DMSO 2 mg/mL Water <1 mg/mL Ethanol <1 mg/mL |
|---|---|
| 敏感性 | 对光敏感 |
| 分子量 | 607.600 g/mol |
| XLogP3 | 6.000 |
| 氢键供体数Hydrogen Bond Donor Count | 0 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 607.22 Da |
| 单同位素质量Monoisotopic Mass | 607.22 Da |
| 拓扑极表面积Topological Polar Surface Area | 69.600 Ų |
| 重原子数Heavy Atom Count | 45 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1110.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 预防措施声明 |
P264: 处理后要彻底洗手。 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | T129642 | |
| 分析证书 | T129642 | |
| 分析证书 | T129642 | |
| 分析证书 | T129642 | |
| 分析证书 | T129642 | |
| 分析证书 | T129642 | |
| 分析证书 | T129642 | |
| 分析证书 | T129642 | |
| 分析证书 | T129642 | |
| 分析证书 | T129642 | |
| 分析证书 | T129642 |
| 1. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.. J Biol Chem, 284 (12): (8023-32). [PMID:19150980] |
| 2. Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM et al.. (2010) Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.. J Med Chem, 53 (19): (7146-55). [PMID:20860370] |
| 3. Peñailillo J et al.. (2021) Analysis of the early response to spinal cord injury identified a key role for mTORC1 signaling in the activation of neural stem progenitor cells.. NPJ Regen Med, 6 (68). [PMID:34686684] |
| 4. Sun Chao-Yue, Talukder Milton, Cao Di, Chen Cun-Wu. (2022) Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells. Frontiers in Pharmacology, 13 [PMID:35814226] [10.3389/fphar.2022.829759] |
| 5. Ping Gao, Xinwei Cheng, Maochang Liu, Hui Peng, Guodong Li, Tianze Shang, Jianqiao Wang, Qianyan Gao, Chenglong Zhu, Zhenpeng Qiu, Chengliang Zhang. (2025) GADD45α is a direct target of TFEB and contributes to tacrolimus-induced chronic nephrotoxicity. JCI Insight, [PMID:39913188] [10.1172/jci.insight.183560] |